Non-integrating lentiviral vectors for specific killing of Epstein-Barr virus nuclear antigen 1-positive B cell lymphoma cells

Journal of Gene Medicine

Volumn 13, Issue 9, 2011, Pages 487-496

  Flynn, Ryan P ^a   Zacharias, Jeana ^a   Zhou, Xianzheng ^b   Cannon, Mark L ^b   Philpott, Nicola J ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

B cell lymphoma; EBNA1; EBV; Family of repeats; Non integrating lentiviral vectors; Thymidine kinase

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; EPSTEIN BARR VIRUS FAMILY OF REPEATS PROTEIN; GANCICLOVIR; LENTIVIRUS VECTOR; NON INTEGRATING LENTIVIRUS VECTOR; THYMIDINE KINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; B CELL LYMPHOMA; CANCER CELL DESTRUCTION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOMA CELL; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TRANSGENE; VIRUS GENOME;

CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELL SURVIVAL; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GANCICLOVIR; GENE EXPRESSION REGULATION; GENE ORDER; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HEK293 CELLS; HIV-1; HUMANS; LYMPHOMA, B-CELL; THYMIDINE KINASE; TRANSCRIPTION, GENETIC; TRANSDUCTION, GENETIC; UP-REGULATION;

HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 4;

EID: 80053392422     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1601     Document Type: Article

References (39)

1. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003; 3: 801-812.
2. Carbone A, Gloghini A, Dotti G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 2008; 13: 577-585.
3. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-815.
4. Leight ER, Sugden B. EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. Rev Med Virol 2000; 10: 83-100.
5. Yates J, Warren N, Reisman D, et al. A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci U S A 1984; 81: 3806-3810.
6. Nanbo A, Sugden A, Sugden B. The coupling of synthesis and partitioning of EBV's plasmid replicon is revealed in live cells. EMBO J 2007; 26: 4252-4262.
7. Baer R, Bankier AT, Biggin MD, et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 1984; 310: 207-211.
8. Rawlins DR, Milman G, Hayward SD, et al. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region. Cell 1985; 42: 859-868.
9. Ambinder RF, Shah WA, Rawlins DR, et al. Definition of the sequence requirements for binding of the EBNA-1 protein to its palindromic target sites in Epstein-Barr virus DNA. J Virol 1990; 64: 2369-2379.
10. Reisman D, Yates J, Sugden B. A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol Cell Biol 1985; 5: 1822-1832.
11. Gahn TA, Schildkraut CL. The Epstein-Barr virus origin of plasmid replication, oriP, contains both the initiation and termination sites of DNA replication. Cell 1989; 58: 527-535.
12. Kanda T, Otter M, Wahl GM. Coupling of mitotic chromosome tethering and replication competence in epstein-Barr virus-based plasmids. Mol Cell Biol 2001; 21: 3576-3588.
13. Deng Z, Lezina L, Chen CJ, et al. Telomeric proteins regulate episomal maintenance of Epstein-Barr virus origin of plasmid replication. Mol Cell 2002; 9: 493-503.
14. Lindner SE, Sugden B. The plasmid replicon of Epstein-Barr virus: mechanistic insights into efficient, licensed, extrachromosomal replication in human cells. Plasmid 2007; 58: 1-12.
15. Reisman D, Sugden B. Trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1. Mol Cell Biol 1986; 6: 3838-3846.
16. Langle-Rouault F, Patzel V, Benavente A, et al. Up to 100-fold increase of apparent gene expression in the presence of Epstein-Barr virus oriP sequences and EBNA1: implications of the nuclear import of plasmids. J Virol 1998; 72: 6181-6185.
17. Wysokenski DA, Yates JL. Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus. J Virol 1989; 63: 2657-2666.
18. Apolonia L, Waddington SN, Fernandes C, et al. Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther 2007; 15: 1947-1954.
19. Cara A, Guarnaccia F, Reitz MS, et al. Self-limiting, cell type-dependent replication of an integrase-defective human immunodeficiency virus type 1 in human primary macrophages but not T lymphocytes. Virology 1995; 208: 242-248.
20. Wu Y. HIV-1 gene expression: lessons from provirus and non-integrated DNA. Retrovirology 2004; 1: 13.
21. Philpott NJ, Thrasher AJ. Use of nonintegrating lentiviral vectors for gene therapy. Hum Gene Ther 2007; 18: 483-489.
22. Arvin A, Campadelli-Fiume G, Mocarski E, et al. Human Herpesviruses. Cambridge University Press: Cambridge, 2007.
23. Demaison C, Parsley K, Brouns G, et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002; 13: 803-813.
24. Burns JC, Friedmann T, Driever W, et al. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci U S A 1993; 90: 8033-8037.
25. Huang X, Guo H, Kang J, et al. Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther 2008; 16: 580-589.
26. Krysan PJ, Haase SB, Calos MP. Isolation of human sequences that replicate autonomously in human cells. Mol Cell Biol 1989; 9: 1026-1033.
27. Aiyar A, Tyree C, Sugden B. The plasmid replicon of EBV consists of multiple cis-acting elements that facilitate DNA synthesis by the cell and a viral maintenance element. EMBO J 1998; 17: 6394-6403.
28. Middleton T, Sugden B. Retention of plasmid DNA in mammalian cells is enhanced by binding of the Epstein-Barr virus replication protein EBNA1. J Virol 1994; 68: 4067-4071.
29. Wade-Martins R, Frampton J, James MR. Long-term stability of large insert genomic DNA episomal shuttle vectors in human cells. Nucleic Acids Res 1999; 27: 1674-1682.
30. Allday MJ, MacGillivray AJ. Epstein-Barr virus nuclear antigen (EBNA): size polymorphism of EBNA 1. J Gen Virol 1985; 66: 1595-1600.
31. Karpova MB, Schoumans J, Ernberg I, et al. Raji revisited: cytogenetics of the original Burkitt's lymphoma cell line. Leukemia 2004; 19: 159-161.
32. Garin MI, Garrett E, Tiberghien P, et al. Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood 2001; 97: 122-129.
33. Stoll SM, Sclimenti CR, Baba EJ, et al. Epstein-Barr virus/human vector provides high-level, long-term expression of alpha1-antitrypsin in mice. Mol Ther 2001; 4: 122-129.
34. Hirai H, Satoh E, Osawa M, et al. Use of EBV-based Vector/HVJ-liposome complex vector for targeted gene therapy of EBV-associated neoplasms. Biochem Biophys Res Commun 1997; 241: 112-118.
35. Judde JG, Spangler G, Magrath I, et al. Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia. Hum Gene Ther 1996; 7: 647-653.
36. Evans TJ, Brooks L, Farrell PJ. A strategy for specific targeting of therapeutic agents to tumour cells of virus-associated cancers. Gene Ther 1997; 4: 264-267.
37. Li JH, Chia M, Shi W, et al. Tumor-targeted gene therapy for nasopharyngeal carcinoma. Cancer Res 2002; 62: 171-178.
38. Feng WH, Westphal E, Mauser A, et al. Use of adenovirus vectors expressing Epstein-Barr virus (EBV) immediate-early protein BZLF1 or BRLF1 to treat EBV-positive tumors. J Virol 2002; 76: 10951-10959.
39. Funke S, Maisner A, Muhlebach MD, et al. Targeted cell entry of lentiviral vectors. Mol Ther 2008; 16: 1427-1436.